160 Health International (FRA:O66) EBITDA per Share: €-0.03 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O66 160 Health International Ltd FRA:O66
8 GF Score
Price €1.06
! 5 Warning Signs
View Full Analysis

What is 160 Health International EBITDA per Share?

160 Health International FRA:O66 -5.84% 8 EBITDA per Share is €-0.03 as of Dec. 2025. GuruFocus rates FRA:O66 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 105 Medical Distribution companies, 160 Health International ranks worse than 68.57% on this metric.

160 Health International's EBITDA per Share for the six months ended in Dec. 2025 was €-0.02. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.03.

During the past 3 years, the average EBITDA per Share Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for 160 Health International's EBITDA per Share or its related term are showing as below:

FRA:O66' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.8   Med: -1.8   Max: -1.8
Current: -1.8

During the past 4 years, the highest 3-Year average EBITDA per Share Growth Rate of 160 Health International was -1.80% per year. The lowest was -1.80% per year. And the median was -1.80% per year.

FRA:O66's 3-Year EBITDA Growth Rate is ranked worse than
68.57% of 105 companies
in the Medical Distribution industry
Industry Median: 5.4 vs FRA:O66: -1.80

160 Health International's EBITDA for the six months ended in Dec. 2025 was €-5.84 Mil.

During the past 3 years, the average EBITDA Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 4 years, the highest 3-Year average EBITDA Growth Rate of 160 Health International was 1.70% per year. The lowest was 1.70% per year. And the median was 1.70% per year.


160 Health International  (FRA:O66) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


160 Health International EBITDA per Share Related Terms


160 Health International EBITDA per Share Historical Data

* Premium members only.

The historical data trend for 160 Health International's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

160 Health International EBITDA per Share Chart

160 Health International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBITDA per Share
-0.03 -0.03 -0.04 -0.03

160 Health International Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA per Share Get a 7-Day Free Trial 0.00 -0.03 -0.00 -0.01 -0.02
FRA:O66
8GF Score
160 Health International Ltd FRA:O66
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

160 Health International EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

160 Health International's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-7.832/303.719
=-0.03

160 Health International's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-5.843/303.719
=-0.02

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of €-0.03 mean?
160 Health International (FRA:O66) has a EBITDA per Share of €-0.03 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on 160 Health International and its competitors. According to the industry distribution chart, 160 Health International ranks #72 out of 105 companies in the Medical Distribution industry, placing it in the top 68.6%.
Is 160 Health International's EBITDA per Share too high?
160 Health International's current EBITDA per Share is €-0.03. Based on the distribution chart, 160 Health International ranks #72 out of 105 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, 160 Health International has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does 160 Health International's EBITDA per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, 160 Health International ranks #72 out of 105 companies for EBITDA per Share. This places 160 Health International in the lower half of its industry. The industry median EBITDA per Share is 5.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Distribution company?
The median EBITDA per Share among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on 160 Health International and its competitors. For the Medical Distribution industry, the median EBITDA per Share is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 160 Health International's current EBITDA per Share is €-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 160 Health International stock overvalued right now?
160 Health International (FRA:O66) has a current EBITDA per Share of €-0.03. The current EBITDA per Share is €-0.03. 160 Health International's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For 160 Health International (FRA:O66), the current EBITDA per Share is €-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

160 Health International Business Description

Other Exchanges 02656:Hong Kong
Address 4078 Dongbin Road, Nanshan Street, 9th, 11th - 12th Floor, Building 2, Yongxin Times Square, Nanshan District, Shenzhen, CHN, 518052
160 Health International Ltd is an experienced pharmaceutical and healthcare product wholesaler and a digital healthcare integrated service provider in China. The company offers a wide assortment of high-quality pharmaceutical and healthcare products under both wholesale and retail models, to address a spectrum of customer needs. In addition, through its online healthcare and wellness service platform, Healthcare 160 Platform. It also provide digital healthcare and wellness solutions, empowering each Platform Participants, including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry.
8GF Score

Get the complete analysis for FRA:O66

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.06
Price